Independent Advisor Alliance Takes Position in Insulet Co. (NASDAQ:PODD)

Independent Advisor Alliance bought a new stake in shares of Insulet Co. (NASDAQ:PODD) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1,141 shares of the medical instruments supplier’s stock, valued at approximately $266,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Fisher Asset Management LLC lifted its stake in shares of Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after purchasing an additional 3,113 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in Insulet by 8.5% during the 3rd quarter. Daiwa Securities Group Inc. now owns 12,378 shares of the medical instruments supplier’s stock worth $2,881,000 after acquiring an additional 973 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares in the last quarter. Swedbank AB boosted its holdings in Insulet by 3.2% in the 3rd quarter. Swedbank AB now owns 21,232 shares of the medical instruments supplier’s stock worth $4,942,000 after acquiring an additional 655 shares during the period. Finally, Algert Global LLC grew its position in Insulet by 393.8% in the third quarter. Algert Global LLC now owns 11,131 shares of the medical instruments supplier’s stock valued at $2,591,000 after acquiring an additional 8,877 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PODD. UBS Group upped their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Piper Sandler upped their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Citigroup lifted their target price on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Barclays increased their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, BTIG Research lifted their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

Shares of PODD stock opened at $266.92 on Friday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $279.40. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market capitalization of $18.72 billion, a price-to-earnings ratio of 45.71, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. The business has a 50 day simple moving average of $243.21 and a 200 day simple moving average of $212.74.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.